Source: Today’s Veterinary Business
FidoCure has received a groundbreaking patent from the U.S. Patent and Trademark Office for a targeted therapy and biomarker to treat canine bladder cancer. Early data suggests this new therapy may outperform traditional treatments like chemotherapy and radiation. Bladder cancer affects 50,000 to 80,000 dogs annually in the U.S. and is often difficult to treat. FidoCure, based in Palo Alto, California, plans to seek FDA approval for its innovative therapy, which is part of an AI-driven protocol using a proprietary dataset of over 2 billion data points from treating thousands of dogs.
CEO Christina Lopes emphasized that the patent validates FidoCure’s unique approach to improving outcomes and quality of life for dogs with cancer. The company, which has eight pending patents, is committed to advancing Veterinary cancer treatment and addressing the unmet needs in treating canine bladder cancer, often ineffective and costly with traditional methods.
Read the full story HERE: https://todaysveterinarybusiness.com/fidocure-patent-090224/